V
VDK NaturaSyn
A newly created high-tech enterprise specializing in the research and development, production and sales of biological health products
About VDK NaturaSyn
VDK NaturaSyn operates as a biotechnology company specializing in the biomanufacturing of high-quality, natural ingredients for the global health and wellness market. Emerging in 2021 from BLRH Biotech Co., Ltd., the company leverages synthetic biology to produce ingredients for food, dietary supplements, and Active Pharmaceutical Ingredients (APIs). This approach is positioned as an alternative to traditional plant extraction, aiming to resolve issues related to production rate, quality control, and environmental impact.
The company's core business involves using microbial cell factories and fermentation technology to create functional substances. The process encompasses four main pillars: exploring metabolic pathways and key enzymes, improving enzyme efficiency through evolution and high-throughput screening, reconstructing microorganisms for optimal yield, and scaling up production in cell factories. VDK NaturaSyn has secured $13.9 million in a Series A funding round in August 2023 from investors including Fortune Capital, CMG SDIC Fund, Addor Capital, and CDIB Capital Group. The company is recorded as generating revenue and proceeded with a Series A2 round in April 2025.
VDK NaturaSyn's product portfolio includes 5-hydroxytryptophan (5-HTP), melatonin, resveratrol, β-carotene, and astaxanthin, which are marketed under trademarks like HTPeace™, MelatoPure®, and VDKPure™. These ingredients are used in health foods, dietary supplements, cosmetics, and pet health products. The company operates from a large campus in Baoding, China, with significant investment in its production and R&D facilities, which include enzyme engineering, genetic engineering, and fermentation labs. VDK NaturaSyn holds numerous certifications, including cGMP, HACCP, ISO22000, FSSC2000, Kosher, and Halal, to meet the needs of a diverse user base across North America, Europe, and Asia.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2024 | $14M | $55M | Huachuang Yida · Addor Capital | ↗ |
Growth signals
Latest recorded traffic for VDK NaturaSyn is 450 monthly website visits, up 164.7% over the last three months. VDK NaturaSyn's team grew 22.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
VDK NaturaSyn in its local ecosystem
The VDK NaturaSyn office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- HYHuachuang Yida
Addor Capital
Other known investors1 additional known investor
CDIB Capital Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about VDK NaturaSyn on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See VDK NaturaSyn’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









